Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 14/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597773 | 1.00 | SORT1 (0.39) | SORT1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL13544293 | 0.91 | SORT1 (0.42) | SORT1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL3594624 | 0.86 | SORT1 (0.38) | SORT1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL3594618 | 0.86 | SORT1 (0.38) | SORT1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL3593614 | 0.73 | NPC1 (0.60) | NPC1RAB9A | |
| SCHEMBL3593609 | 0.73 | NPC1 (0.60) | NPC1RAB9A | |
| SCHEMBL13544067 | 0.72 | MTOR (0.39) | NPC1RAB9AALDH1A1MAPK1MTOR | |
| SCHEMBL3588775 | 0.72 | KDR (0.56) | NPC1RAB9AALDH1A1 | |
| SCHEMBL3588779 | 0.72 | KDR (0.56) | NPC1RAB9AALDH1A1 | |
| SCHEMBL3594481 | 0.72 | TRPV1 (0.49) | NPC1RAB9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | SORT1 4494/4885NPC1 879/4885RAB9A 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.